Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6368636

Title:Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
Inventors:McIntosh, Kevin R.; Ellicott City, MD, USA
Mosca, Joseph D.; Ellicott City, MD, USA
Klyushnenkova, Elena N.; Baltimore, MD, USA
Summary:This invention introduces methods of using mesenchymal stem cells for preventing, reducing or treating transplant rejection, also known as graft-versus-host disease. The invention relates to a method of reducing an immune response to a transplant in a recipient by treating the recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. Methods are provided by which the mesenchymal stem cells may be administered before, during, or after the transplant. Further disclosed is a process for reducing an immune response of effector cells against an alloantigen via contacting the effector cells with a supernatant of mesenchymal stem cells in an amount effective to reduce an immune response against an alloantigen, such that the effector cells upon contact with the alloantigen have a reduced immune response against the alloantigen.
Abstract:A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6368636
Application Number:US1999000427333
Date Filed:26/10/1999
Date Published:09/04/2002
Assignee:Osiris Therapeutics, Inc., Baltimore, MD, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/5/2020